Neuland Laboratories Ltd - Stock Valuation and Financial Performance

BSE: 524558 | NSE: NEULANDLAB | Pharmaceuticals & Drugs | Small Cap

Neuland Laboratories Share Price

12,215.75 233.25 1.95%
as on 04-Oct'24 09:54

DeciZen - make an informed investing decision on Neuland Laboratories

Overall Rating
Bole Toh

1. Quality

2. Valuation

Overvalued

3. Price Trend

Semi Strong

Neuland Laboratories stock performance -

mw4me loader
P/E Ratio (SA):
45.79
Market Cap:
15,373.4 Cr.
52-wk low:
3,612.1
52-wk high:
13,600

Is Neuland Laboratories Ltd an attractive stock to invest in?

1. Is Neuland Laboratories Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Neuland Laboratories Ltd is a average quality company.

2. Is Neuland Laboratories Ltd undervalued or overvalued?

The key valuation ratios of Neuland Laboratories Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Neuland Laboratories Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Neuland Laboratories Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Neuland Laboratories:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Neuland Laboratories Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
ROCE % 15.7%18.5%15.9%4%4%7.8%12.8%9.4%21%33.6%-
Value Creation
Index
0.10.30.1-0.7-0.7-0.4-0.1-0.30.51.5-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 4695105795276677639379511,1911,5591,635
Sales YoY Gr.-8.7%13.5%-8.9%26.4%14.4%22.8%1.5%25.3%30.8%-
Adj EPS 18.529.353.113.815.513.156.850.6131.3233.6261.7
YoY Gr.-58.1%81%-73.9%11.9%-15.5%334%-10.9%159.7%77.9%-
BVPS (₹) 179206.3260273.5541.5549.2608.7650.6769.7994.31,070.9
Adj Net
Profit
16.526.147.212.319.916.872.864.9168300336
Cash Flow from Ops. 13.144.738.911.569.656.618960.4239260-
Debt/CF from Ops. 14.44.14.927.73.34.60.93.80.50.3-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 14.3%18.5%18.5%30.8%
Adj EPS 32.5%72.1%60.3%77.9%
BVPS21%12.9%17.8%29.2%
Share Price 38.7% 90.3% 98.7% 219.6%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
Return on
Equity %
11.715.1132.23.22.49.8818.526.525.3
Op. Profit
Mgn %
14.415.718.59.69.513.515.915.223.729.729.9
Net Profit
Mgn %
3.55.18.22.332.27.86.814.119.220.5
Debt to
Equity
1.210.81.30.30.40.20.30.10.1-
Working Cap
Days
24423322028424222520721819818399
Cash Conv.
Cycle
82871061521211161061231159951

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 25.30%

Sales growth is growing at healthy rate in last 3 years 18.49%

Net Profit is growing at healthy rate in last 3 years 60.25%

Sales growth is good in last 4 quarters at 25.96%

No data to display

Latest Financials - Neuland Laboratories Ltd.

Standalone Consolidated
TTM EPS (₹) 261.7 262
TTM Sales (₹ Cr.) 1,635 1,635
BVPS (₹.) 1,070.9 1,075.4
Reserves (₹ Cr.) 1,361 1,367
P/BV 11.19 11.14
PE 45.79 45.74
From the Market
52 Week Low / High (₹) 3612.05 / 13600.00
All Time Low / High (₹) 14.26 / 13600.00
Market Cap (₹ Cr.) 15,373
Equity (₹ Cr.) 12.8
Face Value (₹) 10
Industry PE 47.7

Management X-Ray of Neuland Laboratories:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Neuland Laboratories

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Sales4695105795276677639379511,1911,559
Operating Expenses 4034304734776096617908099201,097
Manufacturing Costs666271817798116131136157
Material Costs244253263238366380438422478577
Employee Cost 49608596104118144176195249
Other Costs 4455556261659280111114
Operating Profit 66801065058101146142271462
Operating Profit Margin (%) 14.1%15.7%18.3%9.5%8.7%13.3%15.6%15.0%22.8%29.6%
Other Income 1215341621013
Interest 27242119162218131314
Depreciation 15161922263140495360
Exceptional Items 0000000000
Profit Before Tax 24416714205210582215401
Tax 915202437251852101
Profit After Tax 1626461216168064163300
PAT Margin (%) 3.4%5.2%8.0%2.2%2.4%2.1%8.6%6.7%13.7%19.2%
Adjusted EPS (₹)17.829.752.213.312.612.462.649.5127.1233.5
Dividend Payout Ratio (%)8%7%0%0%10%16%8%10%8%6%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24

Equity and Liabilities

Shareholders Fund 1601842322446967067828369881,277
Share Capital 9999131313131313
Reserves 1511752232356836937698239751,264
Minority Interest0000000000
Debt1791691813032102461451968545
Long Term Debt3345301036177881047445
Short Term Debt1461241511991491685792110
Trade Payables1128689129124120157123178199
Others Liabilities 6184383395101159240227328311
Total Liabilities 5115238851,0711,1301,2301,3241,3821,5791,831

Fixed Assets

Gross Block2642924554835757148269139531,076
Accumulated Depreciation14115319386492130166215271
Net Fixed Assets123139436445512623697748738805
CWIP 4140201261042417204146
Investments 8888887411
Inventories113127135175193220248265279350
Trade Receivables129119181194164190218234362374
Cash Equivalents 6912173746181959115
Others Assets90829310611212011991100140
Total Assets 5115238851,0711,1301,2301,3241,3821,5791,831

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Cash Flow From Operating Activity 13453912705718960239260
PBT 24416714205210582215401
Adjustment 36344440395840667862
Changes in Working Capital -39-19-55-3916-4949-67-11-91
Tax Paid -9-12-16-3-5-5-5-21-44-112
Cash Flow From Investing Activity -14-20-42-116-77-49-84-96-61-150
Capex -15-19-41-133-63-48-105-98-65-142
Net Investments 0-1-115-16-61922-15
Others 0001152128
Cash Flow From Financing Activity 1-24010512-5-11438-136-69
Net Proceeds from Shares 2500012500000
Net Proceeds from Borrowing -916-579-3992223-33-28
Interest Paid -18-16-21-22-25-24-18-14-13-14
Dividend Paid -3-2-100-5-3-4-6-13
Others 5-222748-4914-11532-84-14
Net Cash Flow 01-3042-934141
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Ratios
ROE (%)11.2515.4422.394.983.442.2710.817.8617.926.48
ROCE (%)15.7418.4615.944.043.957.8412.839.4420.9933.62
Asset Turnover Ratio0.9610.830.540.610.650.730.70.80.91
PAT to CFO Conversion(x)0.811.730.8514.383.562.360.941.470.87
Working Capital Days
Receivable Days958793129988579879186
Inventory Days7985811071019991988374
Payable Days153143121167126117115121115119

Neuland Laboratories Ltd Stock News

Neuland Laboratories Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Neuland Laboratories on 04-Oct-2024 09:54 is ₹12,215.8.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Oct-2024 09:54 the market cap of Neuland Laboratories stood at ₹15,373.4.
The latest P/E ratio of Neuland Laboratories as of 04-Oct-2024 09:54 is 45.79.
The latest P/B ratio of Neuland Laboratories as of 04-Oct-2024 09:54 is 11.19.
The 52-week high of Neuland Laboratories is ₹13,600 and the 52-week low is ₹3,612.1.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Neuland Laboratories is ₹1,635 ( Cr.) .

About Neuland Laboratories Ltd

Named after Father Nieuwland of Notre dame, Neuland Laboratories was incorporated in 1984 by Dr. D. R. Rao for the manufacture of Salbutamol Sulphate, with mere 40 employees.

It has started its commercial production of Salbutamol Sulphate in the year 1986. It has since grown to become one of the most reliable API source for Pharma Industry with addition of more products in course of years.

Today the company with a total employee strength of 1000+ is the preferred supplier of APIs with unmatched quality and timely delivery. Neuland is a quality conscious, research driven, reliable source of active pharmaceutical ingredients.

Operating from India for over two decades, Neuland is the preferred source for the Pharmaceutical Industry across the globe, with strengths in Research based Chemistry and Manufacturing.

The Company has started its commercial production of Salbutamol Sulphate in the year 1986. It has since grown to become one of the most reliable API source for Pharma Industry with addition of more products in course of years.Today the company with a total employee strength of 1000+ is the preferred supplier of APIs with unmatched quality and timely delivery.

Neuland has two world-class API manufacturing facilities close to the city of Hyderabad, capable in handling complex and hazardous reactions. Safety aspects have been given utmost significance may it be plant installation, equipment, systems and personnel to ensure smooth productivity. Dedicated team of manufacturing with incorporation of latest production techniques guarantees delivery of latest intermediate and product to our customers across the globe.

Product range of the company includes:

  • Anti -Asthmatics
  • Fluoroquinolones
  • Cardiovascular
  • CNS
  • Corticosteroids
  • Anti-Ulcerant
  • Anti-Fungal
  • Anti-Parkinsons
  • Anti-Alzheimers

Achievements/ recognition:

  • Received a string of regulatory approvals from USFDA & EDQM for its major products (e.g., Ciprofloxacin HCl, Salbutamol Sulphate) USFDA systems inspection for its pashamylaram Facility (Unit-II) in the year 1999
  • USFDA systems inspection for its Bonthapally (Unit-I) bringing both facilities under full cGMP compliance in 2004
  • Received cGMP clearance for both facilities from TGA, Australia in 2004.
  • Certificate of suitability for product itraconazole in 2006.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.